$SUND
Sundance Strategies, Inc.

2013 Q2 Form 10-K Financial Statement

#000101041213000195 Filed on July 16, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.030M $70.00K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.034M $98.07K
YoY Change 29312.94%
Operating Profit -$1.034M -$98.07K
YoY Change 29312.94%
Interest Expense $30.07K $6.577K
YoY Change 46166.15%
% of Operating Profit
Other Income/Expense, Net -$30.05K -$6.577K
YoY Change 46133.85%
Pretax Income -$1.064M -$104.7K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.064M -$104.7K
YoY Change 29618.35%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$25.68K -$2.255K
COMMON SHARES
Basic Shares Outstanding 40.80M shares 3.760M
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.260M $550.0K
YoY Change
Cash & Equivalents $1.259M $545.4K
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.259M $545.4K
YoY Change 607884.06% 220716.6%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $12.10M $6.300M
YoY Change
Other Assets $8.573M
YoY Change
Total Long-Term Assets $12.10M $6.299M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.259M $545.4K
Total Long-Term Assets $12.10M $6.299M
Total Assets $13.36M $6.844M
YoY Change 6451700.48% 2770919.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $250.0K $89.08K
YoY Change 64835.06% 4689.35%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $3.000M $3.000M
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $3.253M $3.096M
YoY Change 16691.56% 19453.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.253M $3.096M
Total Long-Term Liabilities $0.00
Total Liabilities $3.253M $3.096M
YoY Change 16691.56% 19453.55%
SHAREHOLDERS EQUITY
Retained Earnings -$1.169M -$104.7K
YoY Change 129.96% -79.26%
Common Stock $11.28M $40.80K
YoY Change 99871.96% 985.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.10M $3.749M
YoY Change
Total Liabilities & Shareholders Equity $13.36M $6.844M
YoY Change 6451700.48% 2770919.03%

Cashflow Statement

Concept 2013 Q2 2013 Q1
OPERATING ACTIVITIES
Net Income -$1.064M -$104.7K
YoY Change 29618.35%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.239M -$3.323M
YoY Change 124923.35%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.952M $3.869M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.952M $3.869M
YoY Change 140339.9%
NET CHANGE
Cash From Operating Activities -$6.239M -$3.323M
Cash From Investing Activities
Cash From Financing Activities $6.952M $3.869M
Net Change In Cash $713.1K $545.4K
YoY Change -1782875.0%
FREE CASH FLOW
Cash From Operating Activities -$6.239M -$3.323M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 sund Deferred Tax Assets Other Limitations
DeferredTaxAssetsOtherLimitations
196786 USD
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Document Type
DocumentType
10-K
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001171838
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40797441 shares
CY2013Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012Q3 dei Entity Public Float
EntityPublicFloat
9981689 USD
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
Sundance Strategies, Inc.
CY2013Q1 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013Q1 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013Q1 sund Capitalized Consultant Fee
CapitalizedConsultantFee
300000 USD
CY2013Q1 sund Common Stock Issued To Founder For Cash Subscription Value
CommonStockIssuedToFounderForCashSubscriptionValue
33275 USD
CY2013Q1 sund Increase Decrease In Unrecognized Tax Benefit Settlements
IncreaseDecreaseInUnrecognizedTaxBenefitSettlements
USD
CY2013Q1 sund Increase Decrease In Unrecognized Tax Benefit Statute Lapse
IncreaseDecreaseInUnrecognizedTaxBenefitStatuteLapse
USD
CY2013Q1 sund Increase Decrease In Unrecognized Tax Benefit Tax Positions
IncreaseDecreaseInUnrecognizedTaxBenefitTaxPositions
USD
CY2013Q1 sund Life Insurance Policies Purchased With Debt
LifeInsurancePoliciesPurchasedWithDebt
2999000 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Expenses Plus Interest In Next Twelve Months
LifeSettlementContractsInvestmentMethodExpensesPlusInterestInNextTwelveMonths
-2015262 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid After Year Five
LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidAfterYearFive
-12537318 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Five
LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFive
-2891481 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Four
LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFour
-3384871 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Three
LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearThree
-3977116 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Two
LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearTwo
-2391893 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid Total
LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidTotal
-27197941 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Premiums Paid And Other Expenses
LifeSettlementContractsInvestmentMethodPremiumsPaidAndOtherExpenses
19145957 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid
LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaid
-69410907 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid After Year Five
LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidAfterYearFive
-34153904 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Next Twelve Months
LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInNextTwelveMonths
-5979462 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Five
LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFive
-6522699 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Four
LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFour
-7577533 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Three
LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearThree
-8558716 USD
CY2013Q1 sund Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Two
LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearTwo
-6618593 USD
CY2013Q1 sund Life Settlement Contracts Portion Of Pledge Agreement Paid In Cash
LifeSettlementContractsPortionOfPledgeAgreementPaidInCash
3000000 USD
CY2013Q1 sund Life Settlement Contracts Purchased Through Pledge Agreement
LifeSettlementContractsPurchasedThroughPledgeAgreement
5999000 USD
CY2013Q1 sund Number Of Shares Of Common Stock Remaining Under Subscription Receivable
NumberOfSharesOfCommonStockRemainingUnderSubscriptionReceivable
4114 shares
CY2013Q1 sund Return Of Premium Provisions On Life Settlement Contracts
ReturnOfPremiumProvisionsOnLifeSettlementContracts
190001 USD
CY2013Q1 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
USD
CY2013Q1 sund Stock Issued For Subscription Agreement Shares
StockIssuedForSubscriptionAgreementShares
3758255 shares
CY2013Q1 sund Stock Issued For Subscription Agreement Value
StockIssuedForSubscriptionAgreementValue
3872975 USD
CY2013Q1 sund Working Capital
WorkingCapital
-2550106 USD
CY2013Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
89082 USD
CY2013Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3850257 USD
CY2013Q1 us-gaap Assets
Assets
6844417 USD
CY2013Q1 us-gaap Assets Current
AssetsCurrent
545417 USD
CY2013Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
6299000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
545417 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
545417 USD
CY2013Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40797441 shares
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40797441 shares
CY2013Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
4235 USD
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
40798 USD
CY2013Q1 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
USD
CY2013Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 624px"> <p style="MARGIN: 0px; text-align: justify"><em>Concentrations of Credit Risk and Major Customers.</em> &nbsp;There is currently only one lender, one seller and one reinsuance provider involved in the Company&#39;s NIBs. This lack of diversification increases the risk of loss.</p> <p style="MARGIN: 0px; text-align: justify"><br /> </p> <p style="MARGIN: 0px; text-align: justify; TEXT-INDENT: 48px"> &nbsp;There is a significant concentration due to the Company only having one entity maintaining 100% of their policies.</p> <!--EndFragment--></div> </div>
CY2013Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-40814 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
53902 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-104651 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2013Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2999000 USD
CY2013Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.04 pure
CY2013Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2013-12-31
CY2013Q1 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
40814 USD
CY2013Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
40814 USD
CY2013Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
USD
CY2013Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
237600 USD
CY2013Q1 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
40814 USD
CY2013Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40814 USD
CY2013Q1 us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 624px"> <p style="MARGIN: 0px; text-align: justify"><strong>(3) NEW ACCOUNTING PRONOUNCEMENTS</strong></p> <p style="MARGIN: 0px; text-align: justify"><br /> </p> <p style="MARGIN: 0px; text-align: justify; TEXT-INDENT: 48px">The Company has reviewed recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</p> <p style="MARGIN: 0px; text-align: justify"><br /> </p> <!--EndFragment--></div> </div>
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2013Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
40814 USD
CY2013Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
35581 USD
CY2013Q1 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
5233 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
81328 USD
CY2013Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
6576 USD
CY2013Q1 us-gaap Liabilities
Liabilities
3095523 USD
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6844417 USD
CY2013Q1 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
15195 USD
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3095523 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Carrying Amount
LifeSettlementContractsInvestmentMethodCarryingAmount
6299000 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Face Value
LifeSettlementContractsInvestmentMethodFaceValue
129228934 USD
CY2013Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3300000 USD
CY2013Q1 us-gaap Interest Expense
InterestExpense
6577 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-98074 USD
CY2013Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
36089 USD
CY2013Q1 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2032-03-31
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Face Value Maturing After Year Five
LifeSettlementContractsInvestmentMethodFaceValueMaturingAfterYearFive
114228934 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months
LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths
USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Face Value Maturing In Year Five
LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFive
15000000 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Face Value Maturing In Year Four
LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour
USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Face Value Maturing In Year Three
LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree
USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Face Value Maturing In Year Two
LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo
USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid
LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid
-42212966 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Number Of Contracts
LifeSettlementContractsInvestmentMethodNumberOfContracts
22 pure
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing After Year Five
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingAfterYearFive
19 pure
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths
0 pure
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Five
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFive
3 pure
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour
0 pure
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Three
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree
0 pure
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo
0 pure
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid After Year Five
LifeSettlementContractsInvestmentMethodPremiumsToBePaidAfterYearFive
-21616586 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths
-3964200 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Year Five
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFive
-3631218 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour
-4192662 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree
-4581600 USD
CY2013Q1 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo
-4226700 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3868740 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3323323 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-104651 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6577 USD
CY2013Q1 us-gaap Notes Payable Current
NotesPayableCurrent
2999000 USD
CY2013Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
3441 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
98074 USD
CY2013Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4000 USD
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3868740 USD
CY2013Q1 us-gaap Professional Fees
ProfessionalFees
44172 USD
CY2013Q1 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
37510 USD
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104651 USD
CY2013Q1 us-gaap Revenues
Revenues
USD
CY2013Q1 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
USD
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
3748894 USD
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
USD
CY2013Q1 us-gaap Stock Issued1
StockIssued1
37510 USD
CY2013Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
3760072 shares
CY2013Q1 us-gaap Stock Issued During Period Shares Issued For Noncash Consideration
StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
37037369 shares
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
33275000 shares
CY2013Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
-15195 USD
CY2013Q1 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
3868740 USD
CY2013Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
USD
CY2013Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
USD
CY2013Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
USD
CY2013Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
USD
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 624px"><!--StartFragment--> <p style="MARGIN: 0px; text-align: justify; TEXT-INDENT: 48px"> <em>Estimates,</em> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN: 0px; text-align: justify"><br /> </p> <!--EndFragment--></div> </div>
CY2013Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
40814 USD
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35469179 shares

Files In Submission

Name View Source Status
0001010412-13-000195-index-headers.html Edgar Link pending
0001010412-13-000195-index.html Edgar Link pending
0001010412-13-000195.txt Edgar Link pending
0001010412-13-000195-xbrl.zip Edgar Link pending
ex311.htm Edgar Link pending
ex312.htm Edgar Link pending
ex32.htm Edgar Link pending
R23.htm Edgar Link pending
f10kannualreport033113lwbcle.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
sund-20130331.xml Edgar Link completed
sund-20130331.xsd Edgar Link pending
sund-20130331_cal.xml Edgar Link unprocessable
sund-20130331_def.xml Edgar Link unprocessable
sund-20130331_lab.xml Edgar Link unprocessable
sund-20130331_pre.xml Edgar Link unprocessable